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WHAT THIS PAPER ADDS
 This paper introduces the saphenous treatment score (STS). It is a novel duplex-derived haemodynamic assessment of the great
saphenous vein. Reﬂux, competency and occlusion are recorded before and after treatment, above and below the knee. Descriptive
outcome terms like recanalisation and length of obliteration are replaced with numerical scores. This study has demonstrated that
the STS is responsive to different treatments and ongoing treatments and shown that it may be used to complement other
assessment tools in evaluating outcomes.a r t i c l e i n f o
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Objectives: To evaluate a duplex-derived score for varicose vein treatments using numerical values of
haemodynamic effectiveness.
Design: The saphenous treatment score (STS) was developed prospectively to compare the effect of
endovenous treatments on reﬂux within saphenous segments.
Patients: Sixty-six patients were randomised to endovenous laser ablation (EVLA) or ultrasound-guided
foam sclerotherapy (UGFS) to the great saphenous vein (GSV).
Methods: Assessments included the Aberdeen varicose vein severity score (AVVSS), the venous clinical
severity score (VCSS), the venous ﬁlling index (VFI) and the STS.
Results: A mean STS of 5.70 decreased to 3.30, P < .0005, post-treatment. The median (IQR) AVVSS, VCSS
and VFI (ml/sec) decreased from 21.52(15.48) to 18.86(11.27), P ¼ .14, from 6(4) to 3(4), P < .0005 and
from 7.1(6.9) to 1.9(.9) P < .0005, respectively. In 15 patients requiring additional UGFS the mean STS
values decreased from 5.8 to 4.13 and then to 2.6 P < .0005, respectively. The individual above and below
knee mean treatment differences in STS on 38 EVLA and 28 UGFS patients were 1.92 and .87 (EVLA)
compared to 1.57and .29 (UGFS) P ¼ .001, respectively.
Conclusions: The STS has been shown to grade the haemodynamic effects of different treatments as well
as ongoing treatments on the GSV.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Endovenous treatments for varicose veins like foam scle-
rotherapy, laser and radio-frequency ablation have evolvedthe American Venous Forum.
boratory, 7th Floor, Ealing
, United Kingdom. Tel.: þ44
Lattimer).
ciety for Vascular Surgery. Publishealongside traditional sapheno-femoral ligation, stripping and
multiple phlebectomies. Combinations of treatments are also
popular with one technique used for the truncal veins and
a different treatment used to obliterate the tributaries.
Treatments aimed at abolishing great saphenous vein (GSV)
reﬂux can have varying results with co-existing areas of reﬂux,
competency and occlusion in the above knee (AK) and below knee
(BK) segments of the same saphenous trunk. These post-treatment
patterns are difﬁcult to standardise with most reports relying on
descriptive terms, like partial recanalisation, rather than using
numerical scores. This is in contrast to other scoring systems,whichd by Elsevier Ltd. All rights reserved.
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treatment.
The current duplex-derived venous segmental disease score
(VSDS)1 has a single outcome value, 1 for reﬂux and 1 for occlusion,
for the length of the GSV and consequently lacks the dynamic
sensitivity to quantify saphenous treatments (Table 1). Thus
a focused, dynamic scoring system on the effects of treatment on
the saphenous trunk is proposed.
The saphenous treatment score (STS) is a duplex-derived hae-
modynamic outcome evaluation which grades the signiﬁcance of
co-existing haemodynamic patterns throughout the saphenous
trunk. It is not an assessment which describes the length of GSV
obliteration. Obliteration is a technical success but if reﬂux is
present in other areas of the GSV this may result in haemodynamic
failure, which will be recorded in the STS. The STS therefore has the
potential to compare endovenous treatments to surgical solutions.
A reﬂuxing BK-GSV has been demonstrated to be clinically
signiﬁcant. The extent of reﬂux below the knee leads to worse
symptoms and signs, with a greater likelihood of residual varicose
veins. If the GSV is ablated for a longer length it is associated with
a better outcome and if a reﬂuxing BK-GSV is neglected then there
are often residual symptoms with an increased need for scle-
rotherapy.2 It is therefore justiﬁed to include the BK-GSV in
a scoring system following treatment since this is likely to have
a clinical impact.
The STS focuses on the haemodynamic post-treatment effects
on the GSV trunk compared to the pre-treatment value. It uses
a weighting system to prioritize reﬂux, competency and oblitera-
tion, and assesses both the AK and BK segments of the GSV.
The aim of this study was to evaluate a haemodynamic scoring
system, the STS, to grade different varicose vein treatments,
ongoing treatments and compare them to other validated
assessments.Methods
Study design
This was a randomised study achieved using sealed envelopes.
Sixty-six consecutive patients (66 legs) received either endovenous
laser ablation (EVLA) or ultrasound-guided foam sclerotherapy
(UGFS) for varicose veins during 2009e2010. Hospital rationing
policy and pre-screening by the family doctor precluded treatment
of patients with varicose veins which were only of cosmetic
concern. Thus all patients had symptoms from their primary vari-
cose veins and they had a C score of the CEAP classiﬁcation of C2e6
and signiﬁcant sapheno-femoral junction (SFJ) reﬂux extending for
at least 10 cm from the junction as determined by duplex ultra-
sound. Patients with deep venous reﬂux, evidence of a current or
past DVT, or sapheno-popliteal junction reﬂux were excluded from
the study.
Pre-treatment assessments included the Aberdeen varicose vein
severity score (AVVSS), the venous clinical severity score (VCSS), air
plethysmography (APG) and a duplex examination. Follow-up wasTable 1
Clinical and duplex scoring systems for evaluating saphenous insufﬁciency. The
VCSS and STS are relatively more dynamic systems.
Static (stage/classiﬁcation) Dynamic (change)
Clinical C part of CEAP VCSS
Duplex VSDS STS
VCSS, Venous Clinical Severity Score; STS, Saphenous Treatment Score; CEAP,
Clinical Etiological Anatomical Pathophysiological; VSDS, Venous Segmental Disease
Score.at 3 weeks and 3 months and included the AVVSS, the VCSS and
colour duplex examinations. Follow-up VFI was performed at 3
months in all patients.
The STS scoring system was compared in ﬁve different
situations:
a) In all patients undergoing endovenous treatment against
AVVSS and the VCSS, before and 3 weeks after intervention.
b) In the subgroup of patients requiring additional foam scle-
rotherapy against the venous ﬁlling index (VFI).
c) Between EVLA and UGFS patients, AK and BK, before and 3
weeks after treatment.
d) Correlations between the absolute values of the STS and the
AVVSS, VCSS and VFI assessments 3 months after treatment.
e) Improvements in the STS at 3 months compared with
improvements in the AVVSS, VCSS and VFI measures.
Improvement was deﬁned as the difference between the pre
and post-treatment values for each assessment tool.
Ethics committee approval was granted from the local ethics
committee (No: 08/H0710) and informed consent was obtained
from participating patients.
Scoring with duplex/STS
Scoring was performed using a portable Sonosite Titan colour
duplex scanner (SonoSite Inc, Bothell, WA98021-3904, USA) with
a linear 7 MHz transducer. All examinations were performed by the
same, experienced clinical vascular scientist (MA). Superﬁcial and
deep veins and their junctions were assessed for reﬂux, compe-
tence and occlusion. Reﬂux was induced using a manual calf
compression and release manoeuvre in the standing position.
Reﬂux duration of >.5 s for superﬁcial veins and >1.0 s for deep
veins was considered signiﬁcant. Occlusion was deﬁned as the
presence of complete luminal obliteration of any length. The mean
GSV diameter was calculated from the average of 3 measurements
taken below the SFJ, at mid thigh and above the knee. Non-
reﬂuxing segments of the GSV, localised dilatations or a saphena
varix were avoided.
An STS1e3 was given to the above knee (AK) and the below knee
(BK) parts of the GSV, demarcated by the popliteal skin crease, in
a standing patient. Straight continuing tributaries of the GSV in
patients with a hypoplastic distal GSV were considered as part of
the GSV. A reﬂuxing anterior-accessory saphenous vein (AASV) was
also included as part of the GSV evaluation provided reﬂux origi-
nated from the proximal GSV. A score of 1 represented complete
occlusion of any length without reﬂux, 2 represented competency
without occlusion or reﬂux and 3 represented the presence of
reﬂux irrespective of co-existing occlusion or competency. The AK
and BK scores were then added to give an STS of 2e6 for the leg. The
STS was then repeated after each treatment. When deriving the
total score the appropriate number was used for each segment (AK
or BK) in legs with co-existing haemodynamic patterns. The scores
in the AK and BK segments were then combined to create the STS,
as shown in Fig. 1 and Table 2.
Air plethysmography
This was performed using the APG-1000 apparatus comprising
a sensor air-cuff, an air-pump and software (ACI Medical LLC, San
Marcos, CA92078, USA).3 The VFI represents the rate of venous
ﬁlling of the calf when the patient stands up after lying supine with
the leg elevated at 45. If elevated (>2 ml/s), it provides a global
assessment of reﬂux. The VFI was measured in all patients prior to
and 3 months after the treatment.
Figure 1. The STS derivation before and after endovenous treatment from duplex
reports. Combinations of downward arrows (reﬂux), shaded areas (occlusion) and
upward arrows (competency) deﬁne mixed disease patterns.
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All EVLA procedures were performed with the ELVeS PainLess
diode laser delivering intermittent energy using a 1470 nm wave-
length ﬁbre (Biolitec, Inc. East Longmeadow, MA, 01028, USA) at
a power setting of 14 W. Tumescent anaesthesia (40 ml of .5%
Bupivacaine in 1000 ml .9% saline) was inﬁltrated around the GSV
throughout the length to be ablated and patients were placed in the
Trendelenburg position prior to laser withdrawal. The distal access
point was decided using a convenient location near the knee. The
distal ablation end point relative to the knee and the energy
delivered in joules/cm were recorded. Varicose tributaries were
treated concurrently under local anaesthetic using phlebectomy
hooks. Crepe bandages were applied for 1 day. A class I anti-
embolism stocking was placed over the bandages at the time ofTable 2
The saphenous treatment scoring system. The above knee (AK) and below knee (BK)
segments are ﬁrst individually evaluated and then combined to give the STS. All
areas of GSV reﬂux and ante-grade ﬂow (competency) are assessed even if they
occur in short segments of the GSV.
Grade (AK or BK)
1 ¼ Occlusion (luminal obliteration) anywhere along the GSV.
2 ¼ Competency anywhere along the GSV
3 ¼ Reﬂux anywhere along the GSV > .5 sa
Weight (AK or BK)
3 ¼ Final score if it is present. It has precedence over 1 and 2.
1 ¼ Final score provided there is no reﬂux. It has precedence
over 2 but not 3.
2 ¼ Final score provided there is no reﬂux or obstruction.
This score should be present in health
STS
2e6 Sum of the AK and the BK score
GSV, Great Saphenous Vein; STS, Saphenous Treatment Score.
a This does not included ambiguous ﬂow patterns within the GSV ‘stump’ above
an occluded GSV (like reﬂux from pelvic or epigastric veins) unless there is deﬁned
reﬂux (>0.5sec) from this into the AASV or thigh tributary.treatment, and patients were advised to wear the stocking for 3
weeks, whenever ambulant.
Foam sclerotherapy
Foam sclerotherapy was initially used to treat the incompetent
GSV. In only a few patients, access to the GSV was via a reﬂuxing
tributary. A maximum of 12 ml of foamwas injected during a single
session.4 Foamwas prepared according to the Tessari technique5 by
agitating 1.2 ml of 1% sodium tetradecylsulphate (Fibro-Vein, STD
Pharmaceuticals, Hereford, HR4 0 EL, UK) in 4.8 ml of air using
a three-way tap and 2 syringes to produce 6 ml of foam. This was
then injected into the saphenous trunk, at knee level, using an 18 G
intravenous cannula, with the patient in the supine position and
the leg elevated at 45. Tumescent anaesthesia was used for UGFS if
the GSV was 8 mm in diameter. Ultrasound was used to visualise
the extent and direction of foam migration within the target vein.
Sufﬁcient foam was delivered to ﬁll the GSV to the level of the SFJ.
All patients had a duplex examination at 3 weeks to screen for
a deep vein thrombosis (DVT). This opportunity was used to assess
the need for further sclerotherapy in both groups of patients (EVLA
and UGFS) if there was persistent AK-GSV reﬂux. This was also
offered to all patients with BK-GSV reﬂux or prominent varicosities.
The ﬁnal decision was made by the patient who was informed that
there was a risk of DVT (<1%) and hyperpigmentation from scle-
rotherapy (<10%). A full length, class II, graduated elastic stocking
with a waist attachment was ﬁtted at the time of the initial and
subsequent treatments with foam (Medi, D-95448 Bayreuth, Ger-
many). Patients were advised to wear the stocking continuously for
3 weeks but could take it off at night during the 3rd week.
Statistical analysis
Data was analysed using SPSS Statistics 17 (SPSS Inc, Chicago,
IL60606, USA). Non-parametric data analysis was used to determine
signiﬁcance between groups (ManneWhitney U test), within groups
(Wilcoxon signed rank test) and to illustrate the effects of ongoing
treatments (Friedman test). Signiﬁcance was achieved when P < .05.
Medians with the inter-quartile range (IQR) were used to illustrate
data in charts. Means were preferred to illustrate STS scores because
they are a discrete variable with few categories in comparison to
medians which are an uninformative measure of location.
Results
Patient characteristics
Thirty-eight patients were randomised to EVLA and 28 to UGFS.
Patients were equally matched in terms of their baseline charac-
teristics as shown in Table 3. The median GSV diameter in EVLA
patients versus UGFS patients was 7.54e12 mm versus 8 (4.5e12)
mm respectively, P ¼ .537 (ManneWhitney). In the EVLA group,
the median energy delivered was 69 (53e90) joules/cm. The
median distal ablation end point was 4 (8e20) cm above the knee
crease. The median volume of foam delivered was 126e12 ml. Three
EVLA patients and 12 UGFS patients received additional scle-
rotherapy at 3 weeks.
Follow-up was complete in all assessments in 66 patients (66
legs) at 3 weeks and in 56 patients (56 legs) at 3 months. The VFI
assessments were completed on 61 patients at 3 months.
The STS against other parameters
Over a quarter of patients started with a competent BK-GSV
(STS ¼ 5) and almost all patients achieved a reduction of 2e4
Table 3
Baseline values in 66 patients (legs) prior to endovenous treatment. Expressed in
median (range, IQR) unless otherwise indicated.
EVLA (n ¼ 38) UGFS (n ¼ 28) P valuea
Age (yrs) 48.3 (15.2)b 50.0 (14.1)b .647c
Male:Female 15:23 13:15 .268d
Unilateral:Bilateral 1:1.53 1:1.8 .064d
C of CEAP C2(16), C3(6),
C4a(7), C4b(3), C5(4),
C6(2)
C2(8), C3(3),
C4a(13), C4b(0),
C5(0), C6(2)
e
AVVSS 19.38 (.86e52.93,
11.58)
24.79 (7.5e50.06,
13.47)
.078
VCSS 6 (2e20, 3) 6 (3e17, 5) .508
VFI (ml/sec) 4.7 (1.2e17.8, 5.08) 4.8 (1.4e15.0, 3.63) .977
STS AK 3 (3e3, 0) 3 (3e3, 0) 1.000
STS BK 3 (1e3, 1) 2.63b 3 (2e3, 1) 2.79b .249
STS Total 6 (4e6, 2) 5.63b 6 (5e6, 1) 5.79b .249
IQR, Inter-Quartile Range; AVVSS, Aberdeen Varicose Vein Severity Score; VCSS,
Venous Clinical Severity Score; VFI, Venous Filling Index; STS, Saphenous Treatment
Score; AK, Above Knee; BK, Below Knee; SD, Standard Deviation.
a ManneWhitney U test.
b Mean (SD).
c t-test for equality of means.
d ChieSquare test.
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was signiﬁcant at both 3weeks (P< .0005) and 3months (P< .0005).
The VCSS (P < .0005) and AVVSS (P ¼ .14) improved at 3 weeks
compared to their pre-treatment values (Fig. 2). Although a trend
was observed in AVVSS it failed to achieve signiﬁcance. After 3
months however, the median (IQR) AVVSS decreased from 21.52
(15.94) to 8.16 (13.3), P < .0005 (Wilcoxon).
At 3 months the VCSS, AVVSS and VFI all decreased signiﬁcantly,
P < .0005 (Wilcoxon). Correlations between the STS against theFigure 2. Improvements in the VCSS (A), AVVSS (B) andAVVSS, VCSS and VFI at 3 months were not signiﬁcant at P ¼ .724,
P ¼ .659 and P ¼ .054 respectively (Spearman). Similarly, correla-
tions on improvements (pre-treatment scores minus post-
treatment scores) at 3 months (Table 4) also failed to reach
signiﬁcance except between the VCSS and the STS. However, this
correlation, was too poor (R2 ¼ .075) to derive meaningful
conclusions.
The STS with ongoing treatments
Fifteen patients received additional sclerotherapy. A stepwise
reduction in the STS was observed after the ﬁrst treatment and ﬁnal
treatment as shown in Fig. 3(A). The ﬁnal treatment was able to
achieve a further reduction of 1e2 points in the STS from a median
of 4 as depicted in Fig. 3(B). It is interesting to note that for those
patients who required additional treatment, the median pre-
treatment VFI was 7.1 ml/s (Fig. 3(C)) compared to 4.6 ml/s for
the whole group (Fig. 3(D)).
The STS with different treatments
The mean of the differences in the pre and post-treatment STS
evaluations (MDSTS) have been used to illustrate the different
effects of endovenous treatments with EVLA and UGFS as shown in
Fig. 4(A). The MDSTS to 2 decimal places represents a scale of
improvement with the higher values representing the greatest
difference. The MDSTS after EVLA was 2.79 compared to 1.86 with
UGFS at 3 weeks (P¼ .001, ManneWhitney U test). Following EVLA,
26.3% of patients had a 4-point improvement in their STS compared
to 7.1% of patients in the UGFS group at 3 weeks, as shown in
Fig. 4(B).STS (C, D), three weeks after endovenous treatment.
Table 4
Improvements in the STS (absolute differences between pre and post-treatment
values) at 3 months correlated against the improvements with other validated
severity assessments (n ¼ 56).
AVVSS VFI STS
P valuea R2b P value R2 P value R2
VCSS .110 .047 .051 .069 .041 .075
AVVSS e e .538 .007 .708 .003
VFI e e e e .748 .002
AVVSS, Aberdeen Varicose Vein Severity Score; VCSS, Venous Clinical Severity Score;
VFI, Venous Filling Index; STS, Saphenous Treatment Score.
a Spearman’s rho signiﬁcance (2-tailed).
b Spearman correlation coefﬁcient.
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with a score between 1 and 3), the MDSTS for the AK and BK scores
between EVLA and UGFS are illustrated in Fig. 4(C) and Fig. 4(D),
respectively. With EVLA, 92.1% of patients achieved a 2-point STS
reduction AK compared to 75.0% of UGFS patients (MDSTS: 1.92 and
1.57 for EVLA and UGFS respectively, P ¼ .039, ManneWhitney U
test). When the BK part of the STS was evaluated this also
decreased, but only 26.3% of EVLA and 7.1% of UGFS patients ach-
ieved a 2 point reduction (MDSTS: .87 and .29, respectively,
P¼ .002, ManneWhitney U test). Most of the UGFS patients (20/28)
had no difference in the BK-STS because the primary treatment was
directed at the AK-GSV (Fig. 4(D)).Figure 3. The stepwise change in mean STS during two treatment sessions (A). The additi
shown in these patients (C) compared to the whole group (D).Discussion
The STS is a ﬂexible, duplex-derived scoring system, which is
able to quantify the haemodynamic effectiveness of treatments for
superﬁcial venous insufﬁciency (SVI). It has the potential to
complement the descriptive duplex evaluation with a graded hae-
modynamic outcome measure. Statistical evaluations of variance
are therefore possible which can be used to assess effectiveness
between both treatments and further interventions.
Air plethysmography is another assessment tool, which can
quantify haemodynamic improvements. It measures the rate of
venous ﬁlling to the calf using the VFI in ml/sec.6,7 Similar to the
VSDS it is a much broader assessment than measurements on the
GSV alone because it quantiﬁes the global haemodynamic effects in
all leg veins. However, compared to duplex, APG is not widely
available which limits its value as a useful assessment tool. It has
been used in this study to support the haemodynamic improve-
ments demonstrated by the STS.
The STS focuses on the haemodynamic effects of treatment on
the saphenous trunks in patients with SVI. The GSV is ﬁrst sub-
divided into AK and BK segments demarcated by the popliteal skin
crease. The presence of co-existing reﬂux, obstruction and
competency are then recorded within each segment. Since reﬂux is
the primary pathophysiological abnormality in SVI it was given the
maximum score of 3. Occlusion (luminal obliteration), anywhere
within the segment, and of any length, was given the best score of 1,
since this was the intended treatment effect. If several scores wereonal beneﬁcial effect of the second treatment (B). The improvement in the VFI is also
Figure 4. Patients have been divided into EVLA and UGFS groups. Three week improvements in the STS are illustrated (A, B). Above knee and below knee components of the STS
have been separated in C and D respectively.
Table 5
Modiﬁcations of the standard STS to accommodate saphenous conservation
surgery.
Endovenous obliteration Saphenous conservation
Score
Reﬂux ¼ 3 Reﬂux ¼ 3
Competency ¼ 2 Occlusion ¼ 2
Occlusion ¼ 1 Competency ¼ 1
Precedence
3 > 1 > 2 3 > 2 > 1
Reﬂux > Occlusion > Competency
STS, Saphenous Treatment Score.
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dence (Reﬂux 3 > Occlusion 1 > Competence 2).
In haemodynamic terms it could be argued that competency is
a favourable outcome. Competency is also a treatment aim in
saphenous conservation surgery where reﬂux is abolished without
saphenous occlusion. Occlusion is given the best score1 after EVLA
and sclerotherapy since it aims to obliterate the saphenous vein. A
patent competent vein may have a greater potential for reﬂux
(recurrence) later on but may also represent treatment (oblitera-
tion) failure, which is why it has been scored half-way between
reﬂux3 and occlusion.1 Furthermore, competency may be visualised
as an intermediate state, which could “improve” (obliteration) or
deteriorate (reﬂux). If the BK-GSV was competent and patent, both
pre and post-treatment, there would be no change in the STS.
Protagonists for saphenous conservation surgery (CHIVA) have
the option to change the scoring by giving competency the
improved score of 1 and occlusion a reduced score of 2. However, it
is important that the order of precedence should remain the same
with reﬂux prioritizing over occlusion and occlusion prioritizing
over competency (Table 5). The STS can also be applied to the small
saphenous vein (SSV).
The treatment of varicose tributaries may have indirect effects
on the GSV. Obliteration of varicosities has shown to provide
competency in saphenous trunks which were originally incom-
petent.812 The STS values may change as a result and this may be
useful for phlebologists who need to assess the haemodynamic
effect of isolated phlebectomies. Nevertheless, the score would not
fall below 1 for each GSV segment.An ideal scoring system should be accurate, ﬂexible, practical,
universal, easy and representative of the disease and treatment
being assessed. The proposed STS may fulﬁl many of these criteria
but not all. If baseline assessments are undertaken then the greatest
treatment effect would be possible only on those patients with the
worst initial scores.
Occasionally patients may have a successful obliteration of the
majority of the AK GSV but reﬂux can still remain within the upper
or lower few centimetres of vein. This would be considered a failure
under the STS with an AK STS score of 3 representing reﬂux.
Although the appropriateness of this would be controversial, the
principle of the STS relies on a haemodynamic outcome evaluation,
and not a technical assessment. Descriptive terms like partial
occlusion or recanalisation can therefore be replaced with numer-
ical scores depending on their haemodynamic signiﬁcance.
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Although a trend in improvement was observed, 3 weeks may be
considered too early to assess improvements in quality of life.
Patients may still have discomfort, which would not allow them to
appreciate the beneﬁts of treatment.
The use of the STS in evaluating treatment comparisons and
ongoing treatments for SVI has been demonstrated. In common
with other assessment systems it improves after endovenous
treatment. The separate scores for AK and BK segments may also be
used in the evaluation of different treatments or combination of
treatments.
Limitations of study
No reproducibility or inter-observer variability measures were
performed on the STS.
Conclusion
The STS is a quantitative, ﬂexible, duplex-derived, scoring
system, which has the potential to assess the haemodynamic
effectiveness of treatments for SVI. This study has shown that the
STS can score and differentiate between the therapeutic impact of
EVLA and UGFS, AK and BK treatment effects, as well as assess the
beneﬁt of further interventions.
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